ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress

09 9 2022 08:15:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

07 9 2022 17:00:00 提供 Nasdaq GlobeNewswire

New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress

06 9 2022 08:00:02 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 9 2022 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors

02 9 2022 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

01 9 2022 08:00:01 提供 Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

23 8 2022 08:00:01 提供 Nasdaq GlobeNewswire

Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients

22 8 2022 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older

10 8 2022 09:00:01 提供 Nasdaq GlobeNewswire

Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update

04 8 2022 16:01:00 提供 Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

04 8 2022 08:00:02 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 8 2022 17:55:54 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock

02 8 2022 21:26:57 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock

02 8 2022 16:02:00 提供 Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

29 7 2022 16:05:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

11 7 2022 08:00:01 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 7 2022 16:04:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

06 6 2022 07:30:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 6 2022 16:16:00 提供 Nasdaq GlobeNewswire

CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

25 5 2022 10:33:12 提供 Nasdaq GlobeNewswire